Related Experiment Video

Updated: May 29, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Future of hepatitis C therapy: development of direct-acting antivirals

Gregory J Dore1, Gail V Matthews, Jürgen Rockstroh

  • 1Viral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales, Australia. gdore@kirby.unsw.edu.au

Current Opinion in HIV and AIDS
|September 8, 2011
PubMed
Abstract

Insights

New direct-acting antiviral (DAA) therapies are transforming hepatitis C virus (HCV) treatment, offering improved sustained virological response rates. While initial DAAs show promise, challenges like toxicity and drug interactions require careful management, especially in coinfection cases.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection remains a significant global health concern.
  • The advent of direct-acting antiviral (DAA) agents marks a new era in HCV therapy.
  • Understanding the efficacy and challenges of DAA-based regimens is crucial for clinical practice.

Purpose of the Study:

  • To review the initial direct-acting antiviral (DAA) agents for hepatitis C virus (HCV) therapy, telaprevir and boceprevir.
  • To discuss future therapeutic strategies and challenges associated with DAA-based treatments.
  • To examine the implications of DAA therapy in the context of HIV/HCV coinfection.

Main Methods:

  • Review of Phase III clinical trial data for telaprevir and boceprevir in combination with pegylated interferon and ribavirin.
  • Analysis of safety, tolerability, and dosing schedules of early DAA agents.
  • Consideration of ongoing Phase II trials in HIV/HCV coinfection populations.

Main Results:

  • Phase III trials demonstrated significant improvements in sustained virological response (SVR) for chronic HCV genotype 1.
  • Treatment duration was shortened from 48 to 24-36 weeks in many patients.
  • Initial DAAs presented challenges including increased toxicity, complex dosing, and drug-drug interactions, particularly in HIV/HCV coinfection.

Conclusions:

  • Direct-acting antiviral (DAA) therapy represents a paradigm shift in hepatitis C virus (HCV) management.
  • The development of DAA agents paves the way for interferon-free combination therapies.
  • Future DAA agents are anticipated to offer improved tolerability and simpler dosing regimens.

More Related Videos

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...